Showing 2031-2040 of 5643 results for "".
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i
- Eyevance Acquires Global Rights to Persistent Corneal Epithelial Defect Treatment Nexagonhttps://modernod.com/news/eyevance-acquires-global-rights-to-persistent-corneal-epithelial-defect-treatment-nexagon/2479822/Eyevance Pharmaceuticals announced a worldwide licensing agreement with OcuNexus Therapeutics for Nexagon, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) nonresponsive to standard of care. Terms of the deal were not disc
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site
- Bayer, Novartis Lose Case Seeking to End NHS Use of Avastin in Wet AMDhttps://modernod.com/news/bayer-novartis-lose-case-seeking-to-end-nhs-use-of-avastin-in-wet-amd/2479853/The UK High Court on Friday ruled that 12 NHS bodies in the north-east of England can continue to use Roche’s Avastin (bevacizumab) for the treatment of wet age-related macular degeneration (AMD) after dismissing a challenge by Bayer and Novartis. In the case, Bayer and Novartis, which mark
- Heidelberg Engineering OCT Angiography Module Now Available in the United Stateshttps://modernod.com/news/heidelberg-engineering-oct-angiography-module-now-available-in-the-united-states/2479879/Heidelberg Engineering announced that it has received FDA clearance for its OCT Angiography Module (OCTA). The additional module is now available for new and existing Spectralis upgradeable diagnostic imaging devices.
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-early-notification-of-fda-acceptance-of-nda-submission-for-roclatan/2479999/Aerie Pharmaceuticals reported that it has received the “Day 74” notification from the FDA earlier than scheduled. The FDA has completed its initial 60-day review of the new drug application (NDA) for Roclatan (netarsudil/latanoprostnetarsudil ophthalmic solution) 0.02%/0.005% and the FDA has det
- Novartis Chairman Says Alcon Worth $20 Billion to $30 Billion: Finanz und Wirtschafthttps://modernod.com/news/novartis-chairman-says-alcon-worth-20-billion-30-billion-finanz-und-wirtschaft/2480052/The chairman of Swiss Novartis expects Alcon to be valued at between $20 billion and $30 billion when the ophthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft, according to a Reuters
- Neuro-Optometric Rehabilitation Association (NORA) Launches Redesigned Website; Accepts Award Nominationshttps://modernod.com/news/neuro-optometric-rehabilitation-association-nora-launches-redesigned-website-accepts-award-nominations/2480061/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the launch of its redesigned website and new domain name, www.noravisionrehab.org, dedicated to educating patients, caregivers, and health care professionals about neurolog
- LayerBio Awarded $1.2 Million from NIH to Develop Sustained-Release Glaucoma Drughttps://modernod.com/news/layerbio-awarded-1-2-million-from-nih-to-develop-sustained-release-glaucoma-drug/2480164/Founded in 2013 as a spin-off from the lab of Dr. Paula Hammond at MIT, LayerBio is developing novel drug delivery products for ophthalmology, wound care, tendon repair and other unmet medical needs. The National Eye Institute at the National I